Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Standard Biotools (LAB) Long-Term Investments (2025)

Standard Biotools (LAB) has disclosed Long-Term Investments for 6 consecutive years, with $19.5 million as the latest value for Q3 2025.

On a quarterly basis, Long-Term Investments changed N/A to $19.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $19.5 million, a N/A change, with the full-year FY2015 number at $6.5 million, down 76.39% from a year prior.
Long-Term Investments was $19.5 million for Q3 2025 at Standard Biotools, up from $6.5 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $19.5 million in Q3 2025 to a low of $19.5 million in Q3 2025.